sb 203580 has been researched along with dinaciclib in 4 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (dinaciclib) | Trials (dinaciclib) | Recent Studies (post-2010) (dinaciclib) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 133 | 12 | 129 |
| Protein | Taxonomy | sb 203580 (IC50) | dinaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0272 | |
| Cyclin-K | Homo sapiens (human) | 0.0227 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0162 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0742 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.049 | |
| Cyclin-A2 | Homo sapiens (human) | 0.002 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.119 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.0028 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0074 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.23 | |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | 0.0039 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.414 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.324 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.1273 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0227 | |
| Cyclin-H | Homo sapiens (human) | 0.17 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.17 | |
| Cyclin-A1 | Homo sapiens (human) | 0.003 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.011 | |
| Heat shock factor protein 1 | Homo sapiens (human) | 0.007 | |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.0219 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 0.0323 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Munoz, L | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Laufer, S; Pillaiyar, T | 1 |
3 review(s) available for sb 203580 and dinaciclib
| Article | Year |
|---|---|
Non-kinase targets of protein kinase inhibitors.
Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Kinases | 2017 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Protein Kinase Inhibitors; SARS-CoV-2; Signal Transduction; Virus Replication | 2022 |
1 other study(ies) available for sb 203580 and dinaciclib
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |